Gilead Sciences Says Regulators Clear CV Buyout

NEW YORK (AP) — Gilead Sciences Inc. said Wednesday that its acquisition of CV Therapeutics Inc. will proceed after regulators ended a mandatory antitrust review period. Gilead, an HIV drug maker based in Foster City, Calif., agreed to buy CV Therapeutics in March for about $1.4 billion. The company said Wednesday that the Federal Trade Commission ended a review required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The tender offer for CV Therapeutics shares is scheduled to end April 14. The purchase would give Gilead control of CV's blood pressure drug candidate darusentan, as well as the angina treatment Ranexa.